CDMO Analytical Development: What Sponsors Should Evaluate

It is difficult to develop a manufacturing process without reliable ways to measure the product.

Was the right material produced?

How pure is it?

Did the process change the product?

Are impurities increasing?

Is the product stable?

Can it be released for the next stage of development?

Those questions depend on analytical methods.

That makes analytical development more than a supporting laboratory service.

For many programs, it is a central part of CMC development and manufacturing.

Analytical development involves creating and refining methods used to characterize, test, and understand a pharmaceutical product or manufacturing process.

The exact methods depend on the modality.

They may be used to evaluate:

• identity
• purity
• potency
• concentration
• impurities
• stability
• product quality attributes
• process performance

Some methods are needed early for development.

Others become important for release, stability, validation, or later regulatory work.

There is no universal analytical package that works for every drug.

A small molecule program may require very different methods from a monoclonal antibody, viral vector, peptide, or cell therapy.

A laboratory can have excellent instrumentation and still lack the specific development expertise a program needs.

Routine testing assumes the analytical method already works.

Early programs may not be there yet.

Method development may be required to determine:

• how the attribute should be measured
• what sample preparation is required
• which conditions produce reliable results
• how sensitive the method needs to be
• how specific the method is to the target measurement

This is scientific development work, not simply running samples through an instrument.

Process development and analytical development are closely connected.

If a team changes a manufacturing parameter, it needs reliable methods to understand what happened to the product.

Analytical data can help identify:

• process improvements
• new impurities
• changes in product quality
• stability issues
• batch-to-batch variability

Weak analytical methods can make process-development decisions much harder.

An early research method may be adequate for initial development.

It may not be suitable for later GMP manufacturing or formal release testing.

As the program progresses, methods may need to become more:

• robust
• reproducible
• controlled
• qualified
• validated where appropriate

The sponsor should understand how the CDMO plans to move analytical methods from early development toward later-stage use.

If analytical methods already exist, they may need to be transferred to the CDMO.

That transfer can uncover differences in:

• equipment
• reagents
• operators
• procedures
• sample preparation
• laboratory environment

A method that performed well at the sponsor's laboratory may not work identically at another site.

Sponsors should therefore include analytical transfer in the overall technology-transfer plan.

A CDMO may perform some analytical testing internally and outsource other methods.

That is not automatically a problem.

The sponsor should simply understand the operating model.

Questions include:

• Which methods are internal?
• Which are outsourced?
• Which laboratories are used?
• Who manages the external relationship?
• How do outsourced tests affect timelines?
• Who owns investigations if a result is unexpected?

The answer can have a meaningful effect on project management.

Analytical requirements can become highly specialized.

For a biologic, the sponsor may need methods related to:

• aggregation
• potency
• product variants
• process-related impurities

For viral vectors, testing may involve:

• vector concentration
• potency
• infectious activity
• residual impurities

For small molecules, methods may focus more heavily on:

• assay
• impurities
• residual solvents
• dissolution
• stability

The right analytical partner should understand the product class, not simply operate generic laboratory equipment.

For some products, potency testing can be one of the more difficult analytical development activities.

The appropriate method depends on the mechanism and product.

Sponsors should identify early whether potency-method development is likely to become a major workstream.

If so, relevant experience should be part of CDMO selection.

Stability data helps teams understand how a product changes over time and under defined storage conditions.

Sponsors should determine:

• required storage conditions
• stability-indicating methods
• sample requirements
• testing intervals
• storage capacity
• who manages the stability program

Stability programs can extend for a long period, which makes operational reliability important.

Manufacturing may finish on schedule while the product remains unavailable because testing is incomplete.

Sponsors should therefore ask about analytical lead times when evaluating project schedules.

Potential bottlenecks include:

• method development
• method transfer
• sample testing
• investigations
• release review

Analytical work should be part of the project critical path, not an afterthought.

Unexpected or out-of-specification results can trigger additional work.

Sponsors should understand the CDMO's process for:

• investigating results
• communicating with the sponsor
• retesting where appropriate
• documenting findings
• determining manufacturing impact

The quality-system details belong in deeper diligence, but the operating approach can still be important during selection.

Using the manufacturing CDMO for analytical development can simplify coordination.

The development team may have direct access to samples and process information.

Using a specialized external analytical laboratory may provide deeper expertise for certain methods.

Neither approach is automatically better.

Sponsors should choose based on:

• technical capability
• timeline
• complexity
• coordination burden
• long-term strategy

Pharma Connect Navigator helps sponsors identify manufacturing partners using structured project requirements.

Sponsors can define the modality, stage, required capabilities, support needs, scale, timing, geography, budget, and regulatory requirements of the program.

PCN helps identify potentially relevant CDMO companies and facilities and provides a structured way to compare project fit.

For programs requiring significant analytical support, that makes it easier to prioritize manufacturers whose broader service offering appears aligned with the project before beginning detailed technical discussions.

Specific analytical methods, laboratory capabilities, transfer requirements, and timelines should still be confirmed directly with the CDMO.